Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
- PMID: 25410759
- PMCID: PMC4378905
- DOI: 10.1002/cncr.29145
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
Abstract
Background: The hypomethylating agents (HMAs) azacitidine and decitabine are most commonly used to treat patients with higher-risk myelodysplastic syndromes (MDS). To the authors' knowledge, the prognosis of patients with low-risk and intermediate-1-risk MDS by the International Prognostic Scoring System (IPSS) after HMA failure has not been explored comprehensively.
Methods: The clinical characteristics and treatment outcome of 438 patients with low-risk and intermediate-1-risk MDS who were treated with HMAs were retrospectively analyzed.
Results: Using the International Working Group response criteria, the overall objective response to HMA was 35% with a median of 6 cycles of HMA administered, and the median response duration was 7 months. Only 7% of patients had disease that transformed into acute myeloid leukemia while receiving therapy. Of the 290 patients who were evaluable at the time of HMA failure, 77% remained in the lower-risk disease categories. On multivariate analysis, baseline neutropenia, intermediate-risk and poor-risk baseline karyotype, and lack of response to HMA were found to be independently associated with a higher risk of disease progression. With a median follow-up of 16 months, the median transformation-free survival and overall survival (OS) after HMA failure were 15 months and 17 months, respectively. On multivariate analysis, only The University of Texas MD Anderson Global Scoring System was found to be independently predictive of outcome, with patients with higher-risk categories having poor transformation-free survival (hazards ratio [HR], 1.5; P = .003) and OS (HR, 1.8; P = .002). The administration of salvage therapy was independently associated with better OS only (HR, 0.8; P = .01).
Conclusions: Outcomes of patients with lower-risk MDS after HMA failure are poor and the treatment of these patients remains an unmet medical need. OS is a reasonable primary endpoint for clinical studies targeting this population.
Keywords: hypomethylating agent failure; low-risk; myelodysplastic syndrome; survival.
© 2014 American Cancer Society.
Conflict of interest statement
Conflict of Interest Disclosures: Dr. Jabbour has received a grant from GlaxoSmithKline for work performed outside of the current study. Dr. Padron has received a grant from the Edward P. Evans Foundation for work performed as part of the current study. Dr. Lancet has acted as a paid consultant for and received research support from Celgene for work performed outside of the current study. Dr. Steensma has acted as a paid consultant for Celgene and Incyte. He also owns stock equity in ARIAD Pharmaceuticals and has been a paid member of the Data Safety Monitoring Board for Amgen and Novartis for work performed outside of the current study. Dr. Sekeres has acted as a paid member of the advisory boards for Celgene, Amgen, and Boehringer Ingelheim for work performed outside of the current study. Dr. Gore has received a grant and personal fees from Celgene for work performed outside of the current study. Dr. List has acted as a paid consultant for Celgene for work performed outside of the current study.
Figures
Similar articles
-
Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.Ann Hematol. 2018 Dec;97(12):2309-2317. doi: 10.1007/s00277-018-3458-7. Epub 2018 Aug 2. Ann Hematol. 2018. PMID: 30073392 Clinical Trial.
-
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.Leuk Res. 2015 May;39(5):520-4. doi: 10.1016/j.leukres.2015.03.006. Epub 2015 Mar 20. Leuk Res. 2015. PMID: 25828745 Free PMC article. Clinical Trial.
-
Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.Biol Blood Marrow Transplant. 2017 Sep;23(9):1509-1514. doi: 10.1016/j.bbmt.2017.05.034. Epub 2017 Jun 30. Biol Blood Marrow Transplant. 2017. PMID: 28600031 Free PMC article.
-
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?Future Oncol. 2021 Dec;17(36):5163-5175. doi: 10.2217/fon-2021-0936. Epub 2021 Oct 12. Future Oncol. 2021. PMID: 34636250 Review.
-
Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure.Leuk Lymphoma. 2017 Nov;58(11):2532-2539. doi: 10.1080/10428194.2017.1307361. Epub 2017 Mar 28. Leuk Lymphoma. 2017. PMID: 28351181 Review.
Cited by
-
Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.Cancers (Basel). 2024 Apr 15;16(8):1503. doi: 10.3390/cancers16081503. Cancers (Basel). 2024. PMID: 38672585 Free PMC article. Review.
-
Defining the mutational profile of lower-risk myelodysplastic neoplasm patients with respect to disease progression using next-generation sequencing and pyrosequencing.Contemp Oncol (Pozn). 2023;27(4):269-279. doi: 10.5114/wo.2023.135365. Epub 2024 Feb 17. Contemp Oncol (Pozn). 2023. PMID: 38405213 Free PMC article.
-
Are We Ready For "Triplet" Therapy in Higher-Risk MDS?Clin Hematol Int. 2023 Nov 3;5(4):88301. doi: 10.46989/001c.88301. eCollection 2023. Clin Hematol Int. 2023. PMID: 37933301 Free PMC article.
-
Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept: a multicenter Chinese study.Ann Hematol. 2023 Nov;102(11):3039-3047. doi: 10.1007/s00277-023-05334-y. Epub 2023 Sep 8. Ann Hematol. 2023. PMID: 37682325
-
What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach.Cancers (Basel). 2023 Apr 12;15(8):2248. doi: 10.3390/cancers15082248. Cancers (Basel). 2023. PMID: 37190176 Free PMC article. Review.
References
-
- Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med. 2009;361:1872–1885. - PubMed
-
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088. - PubMed
-
- Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440. - PubMed
-
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous